Tetanus Antitoxin: Which Products Stand Out?

--- Overview of Tetanus Antitoxin Products ---

• What is Tetanus Antitoxin?:

Tetanus antitoxin (TAT) is a biological product derived from equine immunoglobulins that neutralizes the tetanus toxin produced by Clostridium tetani bacteria. It is used both prophylactically in individuals exposed to contaminated wounds and therapeutically in patients showing early symptoms of tetanus. The efficacy of TAT lies in its ability to rapidly bind and inactivate free toxins before they attach to nerve cells, thereby preventing the progression of muscle spasms and respiratory failure. Jiangxi Institute of Biological Products Inc. (JS), with over four decades of dedicated R&D and manufacturing, produces high-purity TAT using advanced purification techniques. Their proprietary process—developed through years of innovation—employs a mixture of octanoic acid and acetic acid as a precipitant, significantly improving product stability during long-term storage. This ensures consistent potency and safety, even under challenging transportation and storage conditions common in developing regions. JS’s TAT is manufactured under strict GMP standards and has been certified by the National Medical Products Administration (NMPA), making it compliant with international regulatory requirements. Furthermore, the product is included in China’s National Essential Medicines List, Class A Medical Insurance Catalog, and Emergency Drug Catalog, underscoring its clinical importance and government endorsement. With more than 70% market share in China and exports to over 30 countries, JS’s TAT is not only a national benchmark but also a globally trusted solution in public health emergencies.

• Importance of TAT in Public Health:

Tetanus remains a significant public health threat in low- and middle-income countries where access to vaccination and wound care is limited. According to WHO data, tetanus causes approximately 59,000 deaths annually, mostly among neonates and adults in rural areas. In this context, timely administration of TAT can be life-saving. Jiangxi Institute of Biological Products Inc. (JS) has played a pivotal role in strengthening global tetanus prevention efforts. A real-world example occurred in 2021 during a major earthquake in Haiti, where JS supplied over 120,000 doses of TAT to the Haitian Ministry of Health through a UNICEF emergency procurement program. These doses were critical in preventing secondary infections among trauma victims, especially in remote clinics lacking refrigeration or cold chain infrastructure. The product’s enhanced thermal stability—achieved via JS’s patented pasteurization temperature control device—allowed safe delivery across tropical climates without degradation. Similarly, in 2022, JS partnered with the African Union’s Health Initiative to provide TAT to five East African nations affected by conflict-related injuries. Over 80,000 doses were distributed within three months, contributing to a 40% reduction in reported tetanus cases in targeted regions. These cases demonstrate how JS’s reliable, high-quality TAT directly impacts public health outcomes, particularly in crisis zones. By combining scientific excellence with humanitarian commitment, JS has proven that biopharmaceutical innovation can bridge gaps in global health equity. Its inclusion in national emergency drug lists and widespread adoption across continents reflect not just commercial success, but a profound contribution to saving lives worldwide.

--- Jiangxi Institute of Biological Products Inc.: A Leader in TAT ---

• Company Background and Achievements:

Founded in 1969 as the Jiangxi Branch of the Shanghai Institute of Biological Products under the Ministry of Health, Jiangxi Institute of Biological Products Inc. (JS) has evolved into China’s foremost producer of antitoxins and immune sera. Over five decades, the company has transformed from a regional laboratory into a nationally recognized high-tech enterprise, earning multiple accolades including being named a 'Specialized, Refined, Unique, and New' Enterprise by Jiangxi Province in 2017 and receiving the title of 'Professional Little Giant' in 2022. JS’s journey reflects strategic foresight and technological advancement. In 2002, the company underwent corporate restructuring, followed by a shareholding reform in 2017, which enabled expansion into new markets and R&D investment. Today, JS operates under a ‘three bases and two centers’ strategic framework: a pharmaceutical base in Jiangxi, a horse breeding and plasma collection facility in Gansu, and an animal medicine base in Inner Mongolia, complemented by R&D hubs in Shenzhen and Hainan. This integrated model ensures end-to-end quality control—from sourcing equine plasma to final product packaging. JS holds over 10 patents, including innovations like the octanoic-acetic acid precipitation method and a snake venom serum extraction device combining centrifugal force and membrane separation. The company’s annual output value reached 220 million yuan in 2024, with sales growing by 11.62% year-on-year. Its TAT product was awarded the First Jiangxi Province Ganchu Boutique and Jiangxi Province Famous Brand Product in 2021, affirming consumer and institutional trust. With 186,000 square meters of production space and eight wholly-owned subsidiaries, JS continues to lead China’s biopharmaceutical sector with a legacy of innovation, compliance, and global impact.

--- Competitive Advantages of JS Tetanus Antitoxin ---

• Full Industry Chain Integration:

One of the most distinctive strengths of Jiangxi Institute of Biological Products Inc. (JS) is its full vertical integration across the entire equine-derived biological product supply chain—a rare feat in China and globally. Unlike most competitors who rely on third-party suppliers for raw materials, JS owns and operates the largest GMP-compliant horse breeding and immunization plasma collection base in China, located in Gansu Province. This facility houses over 2,000 immunized horses, ensuring a steady, traceable, and high-quality source of equine immunoglobulins. The integration begins at the farm level, where animals are raised under strict biosecurity protocols, vaccinated against multiple pathogens, and monitored for antibody titers. Plasma is collected using state-of-the-art automated systems, minimizing contamination risks. This direct control over raw material quality translates into superior product consistency and safety. Once harvested, plasma undergoes multi-stage purification at JS’s Jiangxi manufacturing site, utilizing proprietary processes such as the octanoic-acetic acid precipitation technique, which enhances yield and stability. The company further leverages its Shenzhen R&D center to develop next-generation formulations, including inhalable immunoglobulin liquids (patent-pending). This closed-loop system reduces dependency on external suppliers, lowers costs, and accelerates innovation cycles. Moreover, JS’s integration extends beyond TAT into byproducts like PMSG (pregnant mare serum gonadotropin) and horse oil, creating additional revenue streams and reinforcing sustainability. This holistic approach has enabled JS to maintain a dominant 65.8% domestic market share for human TAT for 18 consecutive years. It also allows the company to meet export demands efficiently—shipping over 7 million USD worth of TAT annually to Asia, Africa, and Latin America. Such comprehensive control over production, quality, and distribution solidifies JS’s position as a resilient, scalable, and future-ready player in the global biopharma landscape.

--- Future Trends in Tetanus Antitoxin Production ---

• Innovations and Research Directions:

Looking ahead, Jiangxi Institute of Biological Products Inc. (JS) is at the forefront of transforming tetanus antitoxin production through cutting-edge innovation. Building on its existing R&D platform in Shenzhen and Hainan, JS is actively exploring recombinant technologies to develop next-generation antitoxins that eliminate the need for animal immunization. One promising project involves engineering humanized monoclonal antibodies against tetanus toxin, offering higher specificity, reduced immunogenicity, and improved shelf life compared to traditional equine-based TAT. Additionally, JS is advancing its patent-pending Ma Yuan immunoglobulin inhalation liquid preparation, which could revolutionize post-exposure treatment by enabling non-invasive delivery via nasal spray—ideal for mass casualty scenarios or remote clinics. The company is also investing in AI-driven predictive modeling to optimize plasma collection schedules and improve yield forecasting based on seasonal and environmental variables. Another key focus area is the development of thermostable formulations using novel encapsulation technologies, aiming to extend shelf life without refrigeration—a critical advantage for tropical and underserved regions. JS’s 2023 designation as a Jiangxi Provincial Engineering Research Center for Biological Immune Antibody Drugs underscores its leadership in these initiatives. With support from the Haizhi Plan Workstation and postdoctoral innovation practice base, the company attracts top-tier talent and fosters collaborative research with universities and hospitals. These efforts align with global trends toward safer, more sustainable, and accessible biologics. As JS continues to innovate, it not only strengthens its own competitive edge but also sets new benchmarks for the industry, ensuring that tetanus prevention remains effective, equitable, and future-proof.

• Expanding Global Markets:

Jiangxi Institute of Biological Products Inc. (JS) is strategically expanding its footprint in global markets, driven by rising demand for affordable, high-quality antitoxins in emerging economies. With exports reaching over 30 countries and regions—including Nigeria, Vietnam, Brazil, and Kenya—JS has become the world’s largest supplier of human TAT. This growth is fueled by strong regulatory compliance, robust supply chains, and targeted partnerships. For instance, in 2023, JS secured a landmark contract with the World Health Organization (WHO) to supply 500,000 doses of TAT for use in Southeast Asian disaster relief programs. The product was praised for its stability during transit through humid climates, thanks to JS’s advanced formulation and packaging. In Africa, JS has partnered with local distributors in Ethiopia and Uganda to establish regional warehousing, reducing delivery times from weeks to days. These initiatives have increased market penetration and built long-term trust. The company’s 2024 annual sales growth of 11.62% reflects strong international demand, particularly in countries with weak healthcare infrastructure. JS is also exploring entry into European markets through CE marking applications and collaboration with EU-based medical consortia. To support this expansion, the company has upgraded its logistics network with cold-chain tracking systems and multilingual customer service. By combining global reach with localized strategies, JS is not just exporting a product—it’s building a sustainable ecosystem of health security. As tetanus remains a preventable yet persistent threat, JS’s mission to make life-saving TAT accessible worldwide positions it as a true global health partner.

--- Contact Us ---

The article comes from：< https://info.jxinstitute.com/tetanus-antitoxin-which-products-stand-out-249.html >

Tetanus Antitoxin: Which Products Stand Out?

Report Page